Pay in 4 interest-free payments of $7.30 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Scientific References Retatrutide Phase 2 obesity trial GLP-1/GIP/glucagon triple agonist (Jastreboff et al., Eli Lilly)
With stratification by sex, the analyses yielded similar results, with a significantly higher IRR of liver (2.52), pancreatic (33.84), and prostate (2.95) cancers in men and a significantly higher IRR of gallbladder and biliary tract (12.19), pancreatic (13.49), and breast (2.16) cancers in women
Baez-Duarte BG, Mendoza-Carrera F, Garcia-Zapien A, Flores-Martinez SE, Sanchez-Corona J, Zamora-Ginez I, Torres-Rasgado E, Leon-Chavez BA, Perez-Fuentes R, Multidisciplinary Research Group on Diabetes of the Instituto Mexicano del Seguro S
Affordability and access are also part of the discussion
US$ 29.24
US$ 22.67
US$ 27.13
